Patent 11292782 was granted and assigned to Nuvation Bio on April, 2022 by the United States Patent and Trademark Office.
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.